The CHMP backed orforglipron for weight management and type 2 diabetes. Trial users lost about 5 to 11% of body weight over 72 weeks, depending on dose.
Recap by typeshit. Full story at Новости GxP.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
ABC News' chief medical correspondent walks through the latest Novo Nordisk GLP-1 medication and what sets it apart from drugs already on the market.
18:51
A doctor walks through four of the most talked about weight loss drugs in one overview, covering the big names people ask about most.
Investseekers shares notes on the upcoming French rollout of the Wegovy pill and where Novo Nordisk might launch it next in Europe.
Reuters looks at influencers pushing dietary supplements to people on weight loss drugs, turning TikTok into a sales engine for so-called GLP-1 products.
A search result from Polskie Radio on the approval status of tirzepatide for weight loss, with no further detail provided beyond the question itself.
Loading…